Premium
Prognostic value of JAK2V617F mutation in pseudotumor cerebri associated with cerebral venous sinus thrombosis
Author(s) -
Zloto Ofira,
Lubetsky Aharon,
BenBassat Mizrachi Iris,
Kesler Anat,
Quiros Peter A.,
HunaBaron Ruth
Publication year - 2019
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.13032
Subject(s) - medicine , pseudotumor cerebri , sigmoid sinus , thrombocytosis , cerebral venous sinus thrombosis , papilledema , thrombosis , superior sagittal sinus , dural venous sinuses , venous thrombosis , surgery , gastroenterology , intracranial pressure , platelet
Objectives To examine the clinical characteristics and prognosis of cerebral venous sinus thrombosis (CVST) that presented as pseudotumor cerebri (PTC) patients with JAK2V617F mutation. Methods Medical records of all consecutive patients that presented with PTC and a JAK2V617F mutation who were treated were retrospectively reviewed. Data regarding demographics and ocular presenting symptoms and signs, neurological signs, hematological factors treatment, and prognosis were collected. Results The most common presenting symptoms were headache (5 patients, 83.3%) and visual obscurations (5 patients, 83.3%). CVST of the sagittal sinus and sigmoid sinus were the most common site of thrombus. Platelet count and hemoglobin count were higher than normal during follow‐up. There was significant change in the disk edema degree as well as decline in retinal nerve fiber layer (RNFL) thickness ( P < 0.001, P < 0.001, Matched pairs). There was no significant change in visual acuity (VA) or mean deviation (MD) during follow‐up ( P = 0.95, 0.64, respectively, Matched pairs). Conclusions Pseudotumor cerebri resulting from CSVT in our patients with JAK2V617F mutation was frequent in young patients and needed medical and surgical treatment, without improvement in visual functions and in third caused poor visual outcome. Therefore, we believe that a screening test for JAK2V617F mutation should be considered for patients with CVST without known risk factor presenting with PTC, especially when sagittal sinus or sigmoid sinus involvement or thrombocytosis or high hemoglobin are found upon presentation. This might lead to more aggressive management which may improve the visual prognosis of those young patients.